ARTICLE SUMMARY:
Volta Medical offers intra-operative artificial intelligence in the electrophysiology lab to pinpoint triggers of arrhythmia, enabling clinicians to personalize catheter ablation for atrial fibrillation. Enrollment just began for the company’s large randomized controlled trial, designed to prove that doing so improves outcomes in a field where current results leave much to be desired.
Volta Medical (Marseille, France) is out to establish what has never before been definitively proven in the long history of cardiac catheter ablation for atrial fibrillation (AF). In early January, Volta Medical raised a $28 million Series A round led by Gilde Healthcare, with the participation of existing shareholder Pasteur Mutualité.The cash infusion will supportTAILORED AF, a new randomized controlled trial that will test the hypothesis that when guided in real-time in the operating room by Volta’s artificial intelligence-based software VX1, electrophysiologists will be able to execute a personalized ablation strategy that hits a patient’s particular triggers of AF, and that such a strategy is more effective than today’s treatments for this prevalent and deadly disease. (For more on the history of the company, which was founded in 2016 by three renowned electrophysiologists and a data scientist, see “New Atrial Fibrillation Mapping Systems Lay Down Evidence Base,” MedTech Strategist, September 28, 2018.)
